Chemotherapy induced peripheral neuropathic pain

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a severe complication of anticancer therapy.
• CIPN impairs sensory, motor, and autonomic functions, often leading to chemotherapy cessation.
• The pathophysiology of CIPN is not fully understood, contributing to misdiagnosis and undertreatment.

Purpose of the Study:

• To review the current understanding of CIPN pathophysiology.
• To evaluate existing and potential therapeutic strategies for CIPN.
• To identify the need for further research in CIPN prevention and treatment.

Main Methods:

• Literature review of studies on CIPN mechanisms and treatments.
• Analysis of clinical trial data for various pharmacological agents.
• Synthesis of current evidence regarding CIPN management.

Main Results:

• Multiple mechanisms, including mitochondrial dysfunction and abnormal nerve fiber activity, are implicated in CIPN.
• No agents have proven effective in preventing CIPN.
• Duloxetine shows moderate efficacy, while other agents like tricyclic antidepressants and gabapentin have inconclusive results.

Conclusions:

• Effective prevention and treatment protocols for CIPN are lacking.
• Current treatment options offer limited benefits for CIPN.
• Further research into CIPN pathophysiology and novel therapeutic interventions is crucial.